Have you ever been diagnosed with metastatic triple negative breast cancer and received 2 or less lines of chemotherapy for your metastatic disease? If so you may be eligible for a trial to evaluate different treatment combination with avelumab for your metastatic breast cancer.

The purpose of this study is to evaluate a new treatment routine for patients with metastatic HER2 -positive breast cancer. We want to find out what effects, good and bad, using a Poly (ADP-Ribose) polymerase (PARP) inhibitor called niraparib in combination with trastuzumab has on patients with metastatic HER2- positive breast cancer.

Purpose: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? Treatment with T-DM1 and placebo or T-DM1 and tucatinib, for up to 14 cycles, unless the breast cancer returns or the side effects become too severe. If the breast cancer returns while on the study, the treatment will be changed. After completion of T-DM1 and/or placebo, or T-DM1 and tucatinib, the study doctor will continue to follow the patients condition with clinic visits every 6 months for 10 years and watch for side effects and for signs of breast cancer returning.

Have you recently been diagnosed with breast cancer but have not yet started treatment (other than surgery)? You may be able to take part in the UNC CogMAP study. In this study, we want to learn more about cognitive and brain function before and after cancer treatment. This will help us to better understand risk factors for experiencing cognitive difficulties during and after treatment.

This study is assessing the effectiveness and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when given with atezolizumab and bevacizumab as a first-line treatment for unresectable, locally advanced or metastatic patients with hepatocellular carcinoma (HCC). TIGIT is thought to play an important role in HCC's response to immunotherapy treatments such as atezolizumab. This study will assess whether the addition of tiragolumab to atezolizumab and bevacizumab will improve response and clinical outcomes.

In this study, we want to learn if decreasing or increasing your radiation and hormonal therapy has an effect on high risk prostate cancer.

In this study, we want to learn if a combination of two drugs (fianlimab and cemiplimab) is an effective treatment compared to a drug called pembrolizumab for people who have had melanoma removal surgery but are still at high risk for recurrence of the disease.

Have you been diagnosed with a locally advanced or metastatic solid tumor cancer? Are there no available curative treatment options, or has your prior standard of care treatment failed? You may be able to take part in this gene therapy research study to learn more about using your own modified immune cells as a possible treatment.

If you have Testosterone-driven Salivary Gland Cancer, you may be able to participate in a research study testing the anti-cancer drug Darolutamide.

The purpose of this study is to test good and bad effects of different drugs against metastatic brain tumors with altered genes. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in brain metastases and have found several genes that are altered, or mutated. There are medications that target these genes. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your metastatic cancer. The usual approach is defined as care most people get for your metastatic cancer.